Short answer
Insulet Corporation (PODD) filed an 8-K current report with the SEC on June 25, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Jonathan J. Mazelsky appointed Class II director effective July 1, 2026, standing for shareholder election in 2027.
Insulet Corporation 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- Jonathan J. Mazelsky appointed Class II director effective July 1, 2026, standing for shareholder election in 2027
- Former IDEXX Laboratories CEO adds healthcare technology and commercial leadership experience
- Current Dentsply Sirona director, potentially strengthening Insulet’s medical-device industry perspective
- Initial restricted-stock-unit grant valued at $216,548, representing a prorated $260,000 annual award
- Additional cash compensation under Insulet’s non-employee director program
Item 7.01 · Regulation FD Disclosure
- Board appointment of Mr. Mazelsky, signaling a governance change at Insulet
- Exhibit 99.1 contains the appointment announcement and any biographical or strategic context
Item EX-99.1 · Exhibit EX-99.1
- Jonathan Mazelsky appointed independent director effective July 1, 2026
- Former IDEXX CEO joins with medical-device and diagnostics leadership experience
- IDEXX revenues and stock price nearly doubled during his CEO tenure
- Board appointment strengthens Insulet’s strategic and growth expertise around Omnipod expansion
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Insulet Corporation 8-K filings
Get the next PODD 8-K as it lands
Follow PODD for push alerts, or ask the research agent what this filing means.